| For: | Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333 [PMID: 35663066 DOI: 10.12998/wjcc.v10.i14.4327] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm |
| Number | Citing Articles |
| 1 |
Tomas Gabriel Bas, Vannessa Duarte. Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments. Pharmaceuticals 2024; 17(7) doi: 10.3390/ph17070925
|
| 2 |
Nicola Humphry. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance. EMJ Gastroenterology 2022; doi: 10.33590/emjgastroenterol/10106137
|
| 3 |
O. M. Kulchytska, N. V. Kuzminova, S. E. Lozinsky, I. I. Kniazkova, V. M. Khomenko, Yu. L. Shkarivsky, M. M. Velychkovych. EFFICACY, SAFETY, AND FUTURE DIRECTIONS OF ADVANCED THERAPY METHODS FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASES. World of Medicine and Biology 2025; 21(92) doi: 10.26724/2079-8334-2025-2-92-239-248
|
| 4 |
Gionata Fiorino, Ashwin Ananthakrishnan, Russell D. Cohen, Raymond K. Cross, Parakkal Deepak, Francis A. Farraye, Jonas Halfvarson, A. Hillary Steinhart. Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease. Journal of Clinical Medicine 2025; 14(5) doi: 10.3390/jcm14051561
|
| 5 |
Ariel A Jordan, Shubha Bhat, Tauseef Ali, Sarah R Brunskill, Nancy A Clusen, Ross M Maltz, Ced Moise, Xiaofan Sun, Harry J Thomas, Cassie Ray, Mary Harkins-Schwarz, Orna G Ehrlich. Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn’s & Colitis Foundation. Inflammatory Bowel Diseases 2025; 31(7) doi: 10.1093/ibd/izae237
|
| 6 |
Krishna Shah, Klaartje Kok, Ana Ibarra, James O. Lindsay. Inflammatory Bowel Disease Nursing Manual. 2025; doi: 10.1007/978-3-031-87503-8_15
|
| 7 |
Celia Gómez-Labrador, Elena Ricart, Marisa Iborra, Eva Iglesias, María Dolores Martín-Arranz, Luisa de Castro, Ruth De Francisco, Francisco Javier García-Alonso, Ana Sanahuja, Carla J. Gargallo-Puyuelo, Francisco Mesonero, María José Casanova, Míriam Mañosa, Montserrat Rivero, Marta Calvo, Mónica Sierra-Ausin, Carlos González-Muñoza, Xavier Calvet, Santiago García-López, Jordi Guardiola, Lara Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez, Yamile Zabana, Mercè Navarro-Llavat, Rufo Lorente Poyatos, Marta Piqueras, Leyanira Torrealba, Fernando Bermejo, Ángel Ponferrada-Díaz, José L. Pérez-Calle, Manuel Barreiro-de Acosta, Coral Tejido, José Luis Cabriada, Ignacio Marín-Jiménez, Óscar Roncero, Yolanda Ber, Luis Fernández-Salazar, Blau Camps Aler, Alfredo J. Lucendo, Jordina Llaó, Luis Bujanda, Carmen Muñoz Villafranca, Eugeni Domènech, María Chaparro, Javier P. Gisbert. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. Pharmaceutics 2024; 16(5) doi: 10.3390/pharmaceutics16050629
|
| 8 |
Luan Minh Dang, Chuong Dinh Nguyen. Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation. World Journal of Gastroenterology 2026; 32(28): 119462 doi: 10.3748/wjg.119462
|
| 9 |
Shannon White, Ryan Morrow, Ingrid Pan, Edwin F. de Zoeten. Riding the Wave of Adalimumab Biosimilars. Journal of Pediatric Gastroenterology and Nutrition 2023; 76(6) doi: 10.1097/MPG.0000000000003757
|